Repression of miR-29 via MYC leads to increased CD40 signaling in transformed follicular lymphoma

作者信息Daniel Filip, Katerina Litzmanova, Androniki Michaelou, Filip Kledus, Jan Devan, Miroslav Boudny, Eva Hoferkova, Sonali Sharma, Vaclav Seda, Pedro Faria Zeni, Marek Borsky, Kvetoslava Matulova, Leos Kren, Jan Oppelt, Nicolas Blavet, Vaclav Hejret, Milan Urik, Andrea Mareckova, Lisa M Rimsza, Katerina Kamaradova, David Belada, Alice Sykorova, Heidi Mocikova, Marek Trneny, Zuzana Prouzova, Andrew G Evans, Alexey Danilov, Heike Horn, German Ott, Philipp Staber, Jiri Mayer, Jonathan W Friedberg, Andrea Janikova, Marek Mraz
PMID41714403
期刊Leukemia
发布时间2026-02-19
DOI10.1038/s41375-026-02868-8

摘要

Follicular lymphoma (FL) patients are at risk of disease transformation to aggressive high-grade lymphoma (tFL). While several genetic alterations have been implicated in tFL, the role of microenvironmental interactions and post-transcriptional regulation by non-coding RNAs remains poorly understood. We performed the first matched profiling of mRNAs and short non-coding RNAs (miRNAs) in paired FL and tFL samples (n = 11 pairs). This revealed differential expression of 1,075 mRNAs and 19 miRNAs, including repression of miR-29 family in tFL (miR-29a/b/c). Further analysis uncovered that MYC directly transcriptionally represses miR-29 in tFL, resulting in the upregulation of its target TRAF4. TRAF4 upregulation contributes to CD40 signaling being strongly activated in tFL and supports malignant B-cell proliferation. Notably, this increased CD40 pathway activity in 90% of tFL and contrasted with the reduced T-cell numbers in tFL niches. Thus, the MYC-miR-29-TRAF4 axis and increased CD40 signaling propensity may serve as tFL cells' adaptation to reduced numbers of CD40L+ T-cells. Moreover, lower levels of all miR-29s(a/b/c) were associated with shorter overall survival (OS) and progression-free survival in FL (n = 185), including in a multivariate analysis. Low miR-29c was also associated with shorter OS in a validation cohort (n = 92) from the first-line R-CHOP therapy clinical trial (SWOG S0016, NCT00006721).

实验方法

产品清单

名称品牌货号
NextSeq测序仪Illumina--
CellRanger软件----
GraphPad Prism v5.0软件----
Statistica 13.2软件TIBCO Software Inc.--